ClinicalTrials.gg
CompletedNCT02058368Updated Apr 5, 2019Results posted

Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

A Phase 3 interventional study of Dutasteride 0.5mg capsules and Dutasteride placebo capsules in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Completed at 46 sites in 4 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-04-05.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
9th of 48
607 · median 118
Started
2014
with 5 others
Phase 3
11 of 48
1 open now
Registered
16th of 48
by date
Lead sponsor
7 of 48
GlaxoSmithKline

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is one of 6 that started in 2014, is one of 11 in phase 3, and was the 16th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin monotherapy for the improvement of symptoms and health outcomes in an at risk population of benign prostatic hyperplasia (BPH) clinical progression including older men (>=50 years), with moderate-severe symptoms of BPH, enlarged prostates (>=30 cubicentimeter [cc]) and prostate specific antigen (PSA) >= 1.5 nanograms per milliliter (ng/mL). Each subject who met the eligibility criteria at screening will enter a four-week single-blind, placebo run-in period following which each subject will be randomised into a 2 year double-blind treatment phase. The total study duration for each subject will be up to 110 weeks.

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia
  • Quality of Life
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, aged >=50 years
  • Clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE)
  • International Prostate Symptom Score (IPSS) >=12 points at Screening
  • Prostate volume >=30cc (by TRUS)
  • Total serum Prostate Specific Antigen (PSA) >=1.5ng/mL and \<= 10 ng/mL at Screening
  • Maximum urinary flow rate (Qmax) >5mL/sec and 15mL/sec and minimum voided volume of >=125 milliliter (mL) at Screening
  • Asparate aminotransferase () and Alanine aminotransferase (ALT) \< 2x (ULN); alkaline phosphatase and \<= 1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Fluent and literate in local language with the ability to comprehend and record information on the IPSS, BPH-related Health Status (BHS), BPH Impact Index (BII), and Problem Assessment Scale Sexual Function Inventory (PAS- SFI) questionnaires
  • Men with a female partner of must agree to use a condom up to 6 months after the last dose (applies only to countries where the local product monograph for dutasteride mandates condom use for men with a female partner of childbearing potential)

Exclusion criteria

Exclusion Criteria:

  • History or evidence of prostate cancer (e.g. positive or ultrasound, suspicious Digital Rectal Examination [DRE]). Patients with suspicious ultrasound or DRE who have had a negative biopsy within the preceding 6 months and stable PSA are eligible for the study. Note: If total serum PSA is >4ng/mL and unless PSA value has been stable for at least the past 2 years, the investigator should make every appropriate effort to exclude the possibility of prostate cancer, including consideration of prostate biopsy.
  • Previous prostatic surgery (including TURP, laser, transrectal high intensity focused ultrasounds(HIFU), thermotherapy, transurethral needle ablation (TUNA), balloon dilatation, and stent replacement) or other invasive procedures to treat BPH.
  • History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days prior to the Screening Visit. Catheterisation (\<10F) is acceptable with no time restriction.
  • History of AUR within 3 months prior to Screening Visit.
  • Post-void residual volume >250mL (suprapubic ultrasound) at Screening.
  • Any conditions other than BPH, which may in the judgment of the investigator, result in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder , acute or chronic prostatitis, or acute or chronic urinary tract infections).
  • Unstable liver disease (chronic stable and C are acceptable if subject meets entry criteria).
  • History of renal insufficiency, or serum creatinine >1.5 times the at Screening.
  • Any unstable, serious co-existing medical condition(s) including, but not limited to:

    1. Myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.
    2. Postural hypotension, dizziness, vertigo or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury.
    3. Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining or compliance to study procedures in the opinion of the investigator or GSK medical monitor. Investigator may consult with GSK Medical Monitor if condition could interfere with subject's safety
    4. History of breast cancer or clinical breast examination finding suggestive of malignancy.
    5. History of malignancy within the past five years, except for basal cell carcinoma of the skin. Subjects with a priori malignancy who have had no evidence of disease for at least the past 5 years are eligible.
  • Current or Previous Use of the following medications:

    1. Use of any 5-alpha-reductase inhibitor (e.g. finasteride), any drugs with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents), or other drugs noted for gynaecomastia effects, or that could affect prostate volume, within the 6 months preceding the historical TRUS or Screening Visit and throughout the study (other than as study medication). Previous use of dutasteride should not be within 6 months of the baseline or historical TRUS.
    2. Anabolic steroids (subject must discontinue for 6 months prior to study entry to be eligible) and agree not to take them for the duration of the study.
    3. Phytotherapy for BPH within 2 weeks of Screening Visit and/or predicted to need phytotherapy during the study.
    4. Use of any alpha-adrenoreceptor blockers within 2 weeks of Screening Visit (i.e. indoramin, prazosin, terazosin, tamsulosin, alfuzosin, doxazosin, silodosin) and/or predicted to need any alpha blockers other than the study prescribed tamsulosin.
    5. Use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephedrine, ephedrine) or anticholinergics (e.g. oxybutynin,tolterodine, darifenacin, solifenacin,propantheline) or cholinergics (e.g. bethanecol chloride) within 48 hours prior to all uroflowmetry assessments.
  • to any alpha-/beta- adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs.
  • Participation in any or marketed drug trial within 30 days (or 5 half-lives of drug, whichever is the longer) preceding the Screening Visit and/or plans to participate in such a trial during the course of this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
607 participants (actual)

Study arms

  • Experimental
    Arm 1

    Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.

    Drug: Dutasteride 0.5mg capsules · Drug: Dutasteride placebo capsules · Drug: Tamsulosin 0.2mg tablets · Drug: Disintegrating placebo tamsulosin tablet

  • Experimental
    Arm 2

    Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.

    Drug: Dutasteride placebo capsules · Drug: Tamsulosin 0.2mg tablets · Drug: Disintegrating placebo tamsulosin tablet

Interventions

  • Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

  • DrugDutasteride placebo capsules

    Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

  • Commercially available tamsulosin 0.2mg tablets will be supplied.

  • DrugDisintegrating placebo tamsulosin tablet

    Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months

    IPSS (also called IPSS total score) is the sum of the seven questions with each score ranging from 0 (best) to 5 (worst). IPSS was self administered at screening, Baseline and each time-point of Month 3, 6, 9, 12, 15, 18, 21 and 24. Seven questions included are incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. The total IPSS score can range from 0-35 with severity catagories of mild (0 to 7), moderate (8 to 19) or severe (20 to 35). LOCF is defined as carrying forward the last non-missing post-Baseline assessment for participants with missing visit data and/or for participants who discontinued from the study. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Month 24 is the primary timepoint and earlier timepoints are considered secondary. Change from Baseline defined as difference between Post-Baseline value and Baseline value.

    Time frame: Baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months

Secondary outcomes

  1. Percent Change in Prostate Volume From Baseline

    Prostate Volume measurements were conducted annually using Transrectal ultrasound (TRUS). The following calculation was utilized to assess the prostate volume (cc): pi/6 (Anteroposterior Width multiplied by Cephalocaudal Width multiplied by Transverse Width). Post-Baseline prostate volume was calculated at 12 and 24 months. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value and reported as a percentage.

    Time frame: Baseline,12 and 24 months

  2. Number of Participants With IPSS Improvement From Baseline

    Improvement in IPSS was categorized as improvement, no change and worsening. Improvement defined as greater than or equal to 2 points, greater than or equal to 3 points and greater than or equal to 25 percent in participants at months 3,6,9,12,15,18,21 and 24 . Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value.

    Time frame: Baseline and 3, 6, 9,12,15,18,21 and 24 months

  3. Change From Baseline in Maximum Urine Flow Rate (Qmax) by LOCF Approach

    Qmax is defined as maximum urine flow. Qmax was measured with Uroflow meter (Urodyn 1000) at Screening, Baseline, and at Months 6,12,18 and 24. Change from Baseline Qmax at each scheduled post-Baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline Qmax. Baseline value was defined as the latest non-missing assessment either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, 6, 12, 18 and 24 Months

  4. Number of Participants With Qmax Improvement From Baseline by LOCF Approach.

    Qmax change from Baseline was presented using six improvement levels: \>0 milliliter per second (mL/sec) and \>=1 mL/sec through \>=5mL/sec. Qmax percentage change from Baseline was presented using six improvement levels: \>0%, \>=10%, \>=20%, \>=30%, \>=40%, and \>=50%. Here, Qmax improvement of \>= 3 mL/sec and Qmax percentage of \>= 30 % for 24 Months has been summarized. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date.

    Time frame: Baseline 6, 12, 18 and 24 Months

  5. Number of Participants With Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery

    AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization. AUR or BPH-related surgery event details per participant was summarized as first occurring of either AUR or BPH-related surgery.

    Time frame: Up to 24 Months

  6. Number of Subjects With AUR

    AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization.

    Time frame: Up to 24 Months

  7. Number of Participants With BPH-related Surgery

    BPH-related interventions were recorded. BPH-related interventions included adenomectomy, balloon dilatation, electroresection, thermotherapy (microwave or radiofrequency), laser resection, prostatectomy, prostatotomy, transurethral resection of the prostate, transurethral drainage of prostatic abscess, drainage of prostatic cysts, radioactive seeding of the prostate, prostatic urethral stenting, incision of periurethral stricture, ethanol injections into the prostate, transrectal high intensity focussed ultrasound, transurethral needle ablation and transurethral microwave thermotherapy.

    Time frame: Up to 24 Months

  8. Change From Baseline in the BPH-related Health Status (BHS) by LOCF Approach

    BHS was collected as Question 8 the IPSS questionnaire regarding quality of life due to urinary symptom with scores values ranging from 0 (delightful) to 6 (terrible). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from baseline BHS at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BHS.

    Time frame: Baseline, 3, 6, 9, 12, 15, 18, 21 and 24 Months

  9. Change From Baseline in BPH Impact Index (BII) by LOCF Approach

    The BII consists of four questions and BII total score is the sum of four questions. Total score range is 0 (no problem) to 13 (worst value). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline BII at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BII. Change from Baseline was summarized using LOCF approaches.

    Time frame: Baseline 3, 6, 9, 12, 15, 18, 21 and 24 Months

  10. Change From Baseline in Problem Assessment Scale of the Sexual Function Inventory (PAS-SFI)

    PAS SFI consists of three questions each with a range of 0 (Big Problem) to 4 (No Problem). PAS SFI was administered at screening, Baseline and at each month 12 and 24. The total PSI is the sum of the three questions; the total score range is 0 to 12. Change from Baseline PAS SFI at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline PAS SFI. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, 12 and 24 Months

  11. Number of Hospitalization Days

    Duration of hospitalization days due to AUR or BPH-related surgery was recorded.

    Time frame: Up to 24 Months

  12. Number of Participants in a Hospital Ward

    Details of number of participants in different types of wards was recorded. Types of wards included general ward, recovery, intensive care unit, multiple ward types and others

    Time frame: Up to 24 Months

  13. Number of Participants With Hospital Admissions

    Details of participants who were admitted to hospitals related to AUR or BPH-Related surgery has been recorded.

    Time frame: Up to 24 Months

  14. Number of Participants With Non-serious Adverse Events (AE) and Serious AE (SAE)

    An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as resulting in death, life threatening, requires hospitalization or prolongation of hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation that is medically important, All events of possible drug-induced liver injury with hyperbilirubinaemia, male breast cancer and spontaneous abortion of a female partner of a male subject

    Time frame: Up to 24 Months

  15. Change From Baseline in Serum Prostate Specific Antigen (PSA)

    Total serum PSA concentrations were assessed at pre-screening, month 6, 12 and 24. Change from baseline total PSA was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment at each scheduled post-baseline assessment using a general linear model with effects for treatment and baseline total PSA. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline 6, 12 and 24 Months

  16. Number of Participants With Vital Signs Exceeding Threshold Values

    Vital signs included assessment of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. Threshold ranges for SBP ranged from \< 80 mmHg (millimeter of mercury) (lower) to \> 165 mmHg (upper); for DBP ranged from \< 40 mmHg (lower) to \> 105 mmHg (upper) and heart rate \< 40 beats per minute (bpm) (lower) to \> 100 bpm (upper).

    Time frame: Up to 24 Months

  17. Change From Baseline in Post Void Residual Volume

    Post void residual volume was measured suprapubically by ultrasound (immediately following the urinary flow measurement). Post void residual volume change from Baseline distribution at each scheduled post-Baseline assessment was compared with combination treatment (Dut plus Tam) versus tamsulosin treatment using a nonparametric van Elteren test. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, 6, 12, 18 and 24 Months

  18. Number of Participants With Threshold Hematology Value.

    The threshold laboratory values are defined in terms of a multiplicative factor of the testing laboratory's normal range. A laboratory value that is above the upper limit factor multiplied by the upper limit of the normal (ULN) range is considered a high threshold value. A laboratory value that is below the lower limit factor multiplied by the lower limit of the normal (LLN) range is considered a low threshold value. Hematology laboratory parameters assessed included hemoglobin (Hgb), platelet count, white blood cell count (WBC) and red blood cell (RBC) count. Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to 24 Months

  19. Number of Participants With Threshold Clinical Chemistry Value.

    Clinical chemistry laboratory parameters assessed included albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatinine, glucose, potassium, sodium, total bilirubin, total protein and urea/blood urea nitrogen (BUN). Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to 24 Months

  20. Number of Participants With Digital Rectal Examination (DRE)

    DRE evaluation was carried out from normal/diffusely enlarged at Baseline to focal abnormalities at any time post-Baseline. DRE was assessed at screening visit, Month 6, 12, 18 , 24 and final assessment is the latest post-Baseline evaluation that was available. Here, participants with focal abnormalities are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: 6, 12, 18 , 24 months and final assessment

  21. Number of Participants With Clinically Significant Qualitative Breast Examination

    Qualitative breast examination included palpable breast tissue and nipple tenderness. Here, participants with clinically significant abnormalities for palpable breast tissue and nipple tenderness are summarized. Qualitative breast examination was done at screening visit, Month 6, 12, 18 , 24 and final assessment (latest post-Baseline evaluation that was available). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: 6, 12, 18 , 24 months and final assessment

  22. Number of Participants With Suicidal Ideation and Suicidal Behavior

    Suicidality was assessed utilizing the Columbia Suicide Severity Rating Scale (C-SSRS). It included tabular summaries of suicidal ideation and suicidal behavior questions that were administered. Assessments were carried out at Screening, Month 6, Month 12, and Month 24 (or end of treatment) visits. C-SSRS included Question1-2 were for suicidal ideation Question 1: Passive: wish to be dead, Question 2: Active: Non-specific (no method, intent or plan). Questions 6-10 were for suicidal behavior, Question 6: Preparatory Acts or Behavior, Question 7: any aborted attempt, Question 8: Any interrupted attempts, Question 9: Any non-fatal actual suicide attempt, Question 10: Completed suicide. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: 6, 12, 18 , 24 months and final assessment

07

Results

Posted Apr 5, 2019

Participant flow

A randomized, double-blind, parallel group trial to assess the effectiveness and safety of dutasteride (Dut) 0.5 milligram (mg) and tamsulosin (Tam) 0.2 mg combination compared to Tam 0.2 mg. The study consisted of a single-blind, placebo run-in, followed by a 2 year treatment. Eligible subjects were randomized to Dut + Tam or Dut placebo + Tam

Participant flow — Overall Study
MilestonePlacebo +Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Started302305
Completed261251
Not completed4154
Withdrew: Adverse event1520
Withdrew: Lack of efficacy01
Withdrew: Protocol violation04
Withdrew: Lost to follow-up20
Withdrew: Physician decision23
Withdrew: Withdrawal by subject2226

Outcome measures

PrimaryChange From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months

IPSS (also called IPSS total score) is the sum of the seven questions with each score ranging from 0 (best) to 5 (worst). IPSS was self administered at screening, Baseline and each time-point of Month 3, 6, 9, 12, 15, 18, 21 and 24. Seven questions included are incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. The total IPSS score can range from 0-35 with severity catagories of mild (0 to 7), moderate (8 to 19) or severe (20 to 35). LOCF is defined as carrying forward the last non-missing post-Baseline assessment for participants with missing visit data and/or for participants who discontinued from the study. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Month 24 is the primary timepoint and earlier timepoints are considered secondary. Change from Baseline defined as difference between Post-Baseline value and Baseline value.

Time frame:
Baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months
Reported as:
Mean · Score on scale
Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months
Score on scalePlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 3, n=299, 296-4.07 ± 0.34-3.28 ± 0.34
Month 6, n=300, 298-3.73 ± 0.37-3.36 ± 0.37
Month 9, n=300, 298-4.14 ± 0.36-4.28 ± 0.36
Month 12,n= 300, 298-3.93 ± 0.36-4.30 ± 0.36
Month 15, n=300, 298-3.95 ± 0.36-4.90 ± 0.36
Month 18, n=300, 298-3.84 ± 0.38-4.54 ± 0.38
Month 21, n=300, 298-3.94 ± 0.38-4.66 ± 0.38
Month 24, n=300, 298-3.53 ± 0.39-4.96 ± 0.39
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.069 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg + Tam 0.2 mg versus Placebo + Tam 0.2mg are based on t-tests from the general linear model. Reported means are model based adjusted means.) · Mean difference (final values): 0.79 · 95% CI -0.06 to 1.65Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 3.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.43 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg + Tam 0.2 mg versus Placebo + Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means.) · Mean difference (final values): 0.37 · 95% CI -0.55 to 1.29Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 6.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.76 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg + Tam 0.2 mg versus Placebo + Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means.) · Mean difference (final values): -0.14 · 95% CI -1.05 to 0.77Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 9.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.41 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg + Tam 0.2 mg versus Placebo + Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means) · Mean difference (final values): -0.37 · 95% CI -1.27 to 0.53Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 12.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.039 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg+Tam 0.2 mg versus Placebo+ Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means) · Mean difference (final values): -0.95 · 95% CI -1.85 to -0.05Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 15.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.15 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg+Tam 0.2 mg versus Placebo+ Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means) · Mean difference (final values): -0.70 · 95% CI -1.65 to 0.26Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 18.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.15 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg+Tam 0.2 mg versus Placebo+ Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means) · Mean difference (final values): -0.72 · 95% CI -1.68 to 0.25Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 21.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.004 (Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut 0.5 mg+Tam 0.2 mg versus Placebo+ Tam 0.2 mg are based on t-tests from the general linear model. Reported means are model based adjusted means) · Mean difference (final values): -1.43 · 95% CI -2.40 to -0.46Estimates are based on adjusted means from the general linear model. The adjusted mean difference was based on combination minus tamsulosin monotherapy for Month 24.
SecondaryPercent Change in Prostate Volume From Baseline

Prostate Volume measurements were conducted annually using Transrectal ultrasound (TRUS). The following calculation was utilized to assess the prostate volume (cc): pi/6 (Anteroposterior Width multiplied by Cephalocaudal Width multiplied by Transverse Width). Post-Baseline prostate volume was calculated at 12 and 24 months. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value and reported as a percentage.

Time frame:
Baseline,12 and 24 months
Reported as:
Mean · Cubic centimeters (cc)
Percent Change in Prostate Volume From Baseline
Cubic centimeters (cc)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 12, n=287, 2860.2 ± 1.28-22.8 ± 0.99
Month 24, n=287, 2863.6 ± 1.45-24.8 ± 1.06
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Log(Post-Baseline Prostate Volume / Baseline Prostate Volume) = Log(Baseline Prostate Volume) + Treatment + Country. P-values are based on t-tests from the general linear model.) · Mean difference (final values): -23.0 · 95% CI -25.9 to -20.1The adjusted mean estimates, adjusted mean differences, and confidence intervals are expressed in terms of percentage change from Baseline for Month 12.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 · Mean difference (final values): -28.4 · 95% CI -31.7 to -25.2The adjusted mean estimates, adjusted mean differences, and confidence intervals are expressed in terms of percentage change from Baseline for Month 24
SecondaryNumber of Participants With IPSS Improvement From Baseline

Improvement in IPSS was categorized as improvement, no change and worsening. Improvement defined as greater than or equal to 2 points, greater than or equal to 3 points and greater than or equal to 25 percent in participants at months 3,6,9,12,15,18,21 and 24 . Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value.

Time frame:
Baseline and 3, 6, 9,12,15,18,21 and 24 months
Reported as:
Number · Participants
Number of Participants With IPSS Improvement From Baseline
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 3,>= 3 units, n=299, 296160157
Month 3,>= 2 units, n=299,296190176
Month 3,>= 25percent, n=299, 296134123
Month 6,>= 3 units, n=300, 298156156
Month 6,>= 2 units, n=300, 298179176
Month 6,>= 25percent, n=300, 298131133
Month 9,>= 3 units, n=300, 298157177
Month 9,>= 2 units, n=300, 298185193
Month 9,>= 25percent, n=300, 298128150
Month 12,>= 3 units, n=300, 298154171
Month 12,>= 2 units, n=300, 298179191
Month 12,>= 25percent, n=300, 298131154
Month 15,>= 3 units, n=300, 298171186
Month 15,>= 2 units, n=300, 298186203
Month 15,>= 25percent, n=300, 298133160
Month 18,>= 3 units, n=300, 298156171
Month 18,>= 2 units, n=300, 298173187
Month 18,>= 25percent, n=300, 298136148
Month 21,>= 3 units, n=300, 298169178
Month 21,>= 2 units, n=300, 298186194
Month 21,>= 25percent, n=300, 298141161
Month 24,>= 3 units, n=300, 298156184
Month 24,>= 2 units, n=300, 298175197
Month 24,>= 25percent, n=300, 298137169
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.91 (P-value for IPSS improvement \>= 3 units has been presented for Month 3)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.31 (P-value for IPSS improvement \>= 2 units has been presented for Month 3)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.42 (P-value for IPSS improvement \>= 25 percent has been presented for Month 3)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.92 (P-value for IPSS improvement \>= 3 units has been presented for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.89 (P-value for IPSS improvement \>= 2 units has been presented for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.81 (P-value for IPSS improvement \>= 25 percent has been presented for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.080 (P-value for IPSS improvement \>= 3 units has been presented for Month 9)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.42 (P-value for IPSS improvement \>= 2 units has been presented for Month 9)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.060 (P-value for IPSS improvement \>= 25 percent has been presented for Month 9)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.14 (P-value for IPSS improvement \>= 3 units has been presented for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.26 (P-value for IPSS improvement \>= 2 units has been presented for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.048 (P-value for IPSS improvement \>= 25 percent has been presented for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.17 (P-value for IPSS improvement \>= 3 units has been presented for Month 15)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.11 (P-value for IPSS improvement \>= 2 units has been presented for Month 15)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.022 (P-value for IPSS improvement \>= 25 percent has been presented for Month 15)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.18 (P-value for IPSS improvement \>= 3 units has been presented for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.19 (P-value for IPSS improvement \>= 2 units has been presented for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.28 (P-value for IPSS improvement \>= 25 percent has been presented for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.39 (P-value for IPSS improvement \>= 3 units has been presented for Month 21)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.42 (P-value for IPSS improvement \>= 2 units has been presented for Month 21)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.084 (P-value for IPSS improvement \>= 25 percent has been presented for Month 21)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.016 (P-value for IPSS improvement \>= 3 units has been presented for Month 24)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.047 (P-value for IPSS improvement \>= 2 units has been presented for Month 24)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.007 (P-value for IPSS improvement \>= 25 percent has been presented for Month 24)
SecondaryChange From Baseline in Maximum Urine Flow Rate (Qmax) by LOCF Approach

Qmax is defined as maximum urine flow. Qmax was measured with Uroflow meter (Urodyn 1000) at Screening, Baseline, and at Months 6,12,18 and 24. Change from Baseline Qmax at each scheduled post-Baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline Qmax. Baseline value was defined as the latest non-missing assessment either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, 6, 12, 18 and 24 Months
Reported as:
Mean · milliliter per second (mL/sec)
Change From Baseline in Maximum Urine Flow Rate (Qmax) by LOCF Approach
milliliter per second (mL/sec)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, n=270, 2740.62 ± 0.261.54 ± 0.26
Month 12, n=286, 2870.63 ± 0.281.62 ± 0.27
Month 18, n=287, 2880.90 ± 0.332.36 ± 0.33
Month 24, n=287,2900.93 ± 0.322.27 ± 0.32
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.006 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 6) · Mean difference (final values): 0.91 · 95% CI 0.26 to 1.56The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.005 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 12) · Mean difference (final values): 1.00 · 95% CI 0.30 to 1.69The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 18) · Mean difference (final values): 1.46 · 95% CI 0.63 to 2.29The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 24) · Mean difference (final values): 1.34 · 95% CI 0.54 to 2.15The adjusted mean difference was based on Dut+Tam minus Tam
SecondaryNumber of Participants With Qmax Improvement From Baseline by LOCF Approach.

Qmax change from Baseline was presented using six improvement levels: \>0 milliliter per second (mL/sec) and \>=1 mL/sec through \>=5mL/sec. Qmax percentage change from Baseline was presented using six improvement levels: \>0%, \>=10%, \>=20%, \>=30%, \>=40%, and \>=50%. Here, Qmax improvement of \>= 3 mL/sec and Qmax percentage of \>= 30 % for 24 Months has been summarized. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date.

Time frame:
Baseline 6, 12, 18 and 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Qmax Improvement From Baseline by LOCF Approach.
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, >= 3 mL/sec, n=270, 2746986
Month 6, >= 3 %, n=270, 2747086
Month 12, >= 3 mL/sec, n=286, 28764102
Month 12, >= 3 %, n=286, 28773107
Month 18, >= 3 mL/sec, n=287, 28880115
Month 18, >= 3 %, n= 287, 28881111
Month 24, >= 3 mL/sec, n=287, 29077121
Month 24, >= 30 %, n=287, 29071119
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.13 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 3 mL/sec for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.15 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 30 % for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = <.001 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 3 mL/sec for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.003 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 30 % for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.002 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 3 mL/sec for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = 0.009 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 30 % for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = <.001 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 3 mL/sec for Month 24)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Mantel Haenszel · p = <.001 (P-value for Dut+Tam vs. Tam is based on a Mantel-Haenszel test controlling for country for \>= 30 % for Month 24)
SecondaryNumber of Participants With Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery

AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization. AUR or BPH-related surgery event details per participant was summarized as first occurring of either AUR or BPH-related surgery.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Overall154
Year 1 subset82
Year 2 subset72
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Log Rank · p = 0.012 (Relative Risk (hazard ratio) for Dut+Tam vs. Tam is based on the Cox Proportional Hazards Model with stratification by country.) · Cox proportional hazard: 0.27 · 95% CI 0.09 to 0.81
SecondaryNumber of Subjects With AUR

AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Subjects With AUR
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Overall132
Year 1 subset82
Year 2 subset50
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Log Rank · p = 0.005 (Relative Risk (hazard ratio) for Dut+Tam vs. Tam is based on the Cox Proportional Hazards Model with stratification by country.) · Cox proportional hazard: 0.15 · 95% CI 0.03 to 0.68
SecondaryNumber of Participants With BPH-related Surgery

BPH-related interventions were recorded. BPH-related interventions included adenomectomy, balloon dilatation, electroresection, thermotherapy (microwave or radiofrequency), laser resection, prostatectomy, prostatotomy, transurethral resection of the prostate, transurethral drainage of prostatic abscess, drainage of prostatic cysts, radioactive seeding of the prostate, prostatic urethral stenting, incision of periurethral stricture, ethanol injections into the prostate, transrectal high intensity focussed ultrasound, transurethral needle ablation and transurethral microwave thermotherapy.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With BPH-related Surgery
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Overall32
Year 1 subset00
Year 2 subset32
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Log Rank · p = 0.68 (Relative Risk (hazard ratio) for Dut+Tam vs. Tam is based on the Cox Proportional Hazards Model with stratification by country.) · Cox proportional hazard: 0.69 · 95% CI 0.11 to 4.11
SecondaryChange From Baseline in the BPH-related Health Status (BHS) by LOCF Approach

BHS was collected as Question 8 the IPSS questionnaire regarding quality of life due to urinary symptom with scores values ranging from 0 (delightful) to 6 (terrible). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from baseline BHS at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BHS.

Time frame:
Baseline, 3, 6, 9, 12, 15, 18, 21 and 24 Months
Reported as:
Mean · Scores on scale
Change From Baseline in the BPH-related Health Status (BHS) by LOCF Approach
Scores on scalePlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 3, n=299, 296-0.88 ± 0.08-0.85 ± 0.08
Month 6, n=300,298-0.89 ± 0.08-0.73 ± 0.08
Month 9, n=300, 298-1.08 ± 0.08-0.95 ± 0.08
Month 12, n=300, 298-0.87 ± 0.08-0.90 ± 0.08
Month 15, n=300, 298-0.93 ± 0.08-1.02 ± 0.08
Month 18, n=300, 298-0.92 ± 0.08-1.00 ± 0.08
Month 21, n=300, 298-1.08 ± 0.09-1.02 ± 0.09
Month 24, n=300, 298-1.00 ± 0.08-1.16 ± 0.08
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.83 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Country + Baseline Value for Month 3) · Mean difference (final values): 0.02 · 95% CI -0.17 to 0.21The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.11 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Country + Baseline Value for Month 6) · Mean difference (final values): 0.16 · 95% CI -0.04 to 0.36The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.21 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Country + Baseline Value for Month 9) · Mean difference (final values): 0.13 · 95% CI -0.07 to 0.34The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.80 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Country + Baseline Value for Month 12) · Mean difference (final values): -0.03 · 95% CI -0.23 to 0.18The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.37 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 15) · Mean difference (final values): -0.30 · 95% CI -0.30 to 0.11The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.44 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 18) · Mean difference (final values): -0.08 · 95% CI -0.30 to 0.13The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.60 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 21) · Mean difference (final values): 0.06 · 95% CI -0.16 to 0.28The adjusted mean difference was based on Dut+Tam minus Tam
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.16 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value for Month 24) · Mean difference (final values): -0.15 · 95% CI -0.37 to 0.06The adjusted mean difference was based on Dut+Tam minus Tam
SecondaryChange From Baseline in BPH Impact Index (BII) by LOCF Approach

The BII consists of four questions and BII total score is the sum of four questions. Total score range is 0 (no problem) to 13 (worst value). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline BII at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BII. Change from Baseline was summarized using LOCF approaches.

Time frame:
Baseline 3, 6, 9, 12, 15, 18, 21 and 24 Months
Reported as:
Mean · Scores on scale
Change From Baseline in BPH Impact Index (BII) by LOCF Approach
Scores on scalePlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 3, n=299, 296-1.48 ± 0.14-1.23 ± 0.14
Month 6, n=300, 298-1.28 ± 0.15-1.08 ± 0.16
Month 9, n=300, 298-1.55 ± 0.15-1.26 ± 0.16
Month 12, n=300, 298-1.39 ± 0.16-1.24 ± 0.16
Month 15, n=300, 298-1.30 ± 0.16-1.41 ± 0.16
Month 18, n=300, 298-1.16 ± 0.16-1.28 ± 0.16
Month 21, n=300, 298-1.12 ± 0.17-1.27 ± 0.17
Month 24, n=300, 298-1.02 ± 0.17-1.48 ± 0.17
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.17 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): 0.25 · 95% CI -0.11 to 0.62The adjusted mean difference was based on Dut+Tam minus Tam for Month 3
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.33 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): 0.20 · 95% CI -0.20 to 0.59The adjusted mean difference was based on Dut+Tam minus Tam for Month 6
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.15 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): 0.29 · 95% CI -0.10 to 0.68The adjusted mean difference was based on Dut+Tam minus Tam for Month 9
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.46 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): 0.15 · 95% CI -0.25 to 0.55The adjusted mean difference was based on Dut+Tam minus Tam for Month 12
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.59 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Median difference (final values): -0.11 · 95% CI -0.51 to 0.29The adjusted mean difference was based on Dut+Tam minus Tam for Month 15
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.56 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): -0.12 · 95% CI -0.52 to 0.28The adjusted mean difference was based on Dut+Tam minus Tam for Month 18
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.51 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): -0.14 · 95% CI -0.56 to 0.28The adjusted mean difference was based on Dut+Tam minus Tam for Month 21
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.034 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model.) · Mean difference (final values): -0.46 · 95% CI -0.88 to -0.03The adjusted mean difference was based on Dut+Tam minus Tam for Month 24
SecondaryChange From Baseline in Problem Assessment Scale of the Sexual Function Inventory (PAS-SFI)

PAS SFI consists of three questions each with a range of 0 (Big Problem) to 4 (No Problem). PAS SFI was administered at screening, Baseline and at each month 12 and 24. The total PSI is the sum of the three questions; the total score range is 0 to 12. Change from Baseline PAS SFI at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline PAS SFI. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, 12 and 24 Months
Reported as:
Mean · Scores on scale
Change From Baseline in Problem Assessment Scale of the Sexual Function Inventory (PAS-SFI)
Scores on scalePlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 12, n=291, 2930.11 ± 0.21-0.91 ± 0.20
Month 24, n=291, 294-0.11 ± 0.21-0.82 ± 0.21
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Country + Baseline Value.P-values for Dut+Tam versus Tam are based on t-tests from the general linear model for Month 12) · Mean difference (final values): -1.02 · 95% CI -1.54 to -0.50The adjusted mean difference was based on Dut+Tam minus Tam.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = 0.009 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Country + Baseline Value. P-values for Dut+Tam versus Tam are based on t-tests from the general linear model for Month 24) · Mean difference (final values): -0.70 · 95% CI -1.23 to -0.18The adjusted mean difference was based on Dut+Tam minus Tam.
SecondaryNumber of Hospitalization Days

Duration of hospitalization days due to AUR or BPH-related surgery was recorded.

Time frame:
Up to 24 Months
Reported as:
Median · Days
Number of Hospitalization Days
DaysPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Number of Hospitalization Days10.0 (6 to 18)9.0 (7 to 12)
SecondaryNumber of Participants in a Hospital Ward

Details of number of participants in different types of wards was recorded. Types of wards included general ward, recovery, intensive care unit, multiple ward types and others

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants in a Hospital Ward
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
General ward20
Recovery01
Other10
SecondaryNumber of Participants With Hospital Admissions

Details of participants who were admitted to hospitals related to AUR or BPH-Related surgery has been recorded.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Hospital Admissions
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Out-patient50
In-patient63
SecondaryNumber of Participants With Non-serious Adverse Events (AE) and Serious AE (SAE)

An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as resulting in death, life threatening, requires hospitalization or prolongation of hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation that is medically important, All events of possible drug-induced liver injury with hyperbilirubinaemia, male breast cancer and spontaneous abortion of a female partner of a male subject

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AE) and Serious AE (SAE)
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Any Non-serious AE203208
Any SAE5249
SecondaryChange From Baseline in Serum Prostate Specific Antigen (PSA)

Total serum PSA concentrations were assessed at pre-screening, month 6, 12 and 24. Change from baseline total PSA was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment at each scheduled post-baseline assessment using a general linear model with effects for treatment and baseline total PSA. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline 6, 12 and 24 Months
Reported as:
Mean · nanogram/milliliter (ng/mL)
Change From Baseline in Serum Prostate Specific Antigen (PSA)
nanogram/milliliter (ng/mL)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, n=292, 2940.2 ± 0.09-1.7 ± 0.08
Month 12, n=293, 2940.2 ± 0.08-1.9 ± 0.08
Month 24, n=293, 2950.7 ± 0.16-2.0 ± 0.16
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Baseline Value for Month 6) · Mean difference (final values): -1.9 · 95% CI -2.1 to -1.6The adjusted mean difference was based on Dut+Tam minus Tam.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Baseline Value for Month 12) · Mean difference (final values): -2.1 · 95% CI -2.3 to -1.9The adjusted mean difference was based on Dut+Tam minus Tam.
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · General linear model · p = <.001 (Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Baseline Value for Month 24) · Mean difference (final values): -2.7 · 95% CI -3.1 to -2.2The adjusted mean difference was based on Dut+Tam minus Tam.
SecondaryNumber of Participants With Vital Signs Exceeding Threshold Values

Vital signs included assessment of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. Threshold ranges for SBP ranged from \< 80 mmHg (millimeter of mercury) (lower) to \> 165 mmHg (upper); for DBP ranged from \< 40 mmHg (lower) to \> 105 mmHg (upper) and heart rate \< 40 beats per minute (bpm) (lower) to \> 100 bpm (upper).

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Exceeding Threshold Values
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
SBP, < 80 mmHg00
SBP, > 165 mmHg1013
SBP, either threshold1013
DBP, < 40 mmHg00
DBP, > 105 mmHg62
DBP, either threshold62
Heart rate, < 40 bpm00
Heart rate, > 100 bpm1114
Heart rate, either threshold1114
SecondaryChange From Baseline in Post Void Residual Volume

Post void residual volume was measured suprapubically by ultrasound (immediately following the urinary flow measurement). Post void residual volume change from Baseline distribution at each scheduled post-Baseline assessment was compared with combination treatment (Dut plus Tam) versus tamsulosin treatment using a nonparametric van Elteren test. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, 6, 12, 18 and 24 Months
Reported as:
Mean · mL
Change From Baseline in Post Void Residual Volume
mLPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, n=288, 290-4.8 ± 52.59-3.0 ± 59.56
Month 12, n=291, 2921.5 ± 60.94-1.4 ± 59.19
Month 18, n=291, 292-2.6 ± 55.67-1.3 ± 63.98
Month 24, n=291, 2922.6 ± 64.71-2.6 ± 62.01
Statistical analysis
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Van Elteren test · p = 0.77 (P-value for Dut+Tam vs. Tam is based on a van Elteren test with stratification by country for Month 6)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Van Elteren test · p = 0.84 (P-value for Dut+Tam vs. Tam is based on a van Elteren test with stratification by country for Month 12)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Van Elteren test · p = 0.98 (P-value for Dut+Tam vs. Tam is based on a van Elteren test with stratification by country for Month 18)
  • Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg · Van Elteren test · p = 0.28 (P-value for Dut+Tam vs. Tam is based on a van Elteren test with stratification by country for Month 24)
SecondaryNumber of Participants With Threshold Hematology Value.

The threshold laboratory values are defined in terms of a multiplicative factor of the testing laboratory's normal range. A laboratory value that is above the upper limit factor multiplied by the upper limit of the normal (ULN) range is considered a high threshold value. A laboratory value that is below the lower limit factor multiplied by the lower limit of the normal (LLN) range is considered a low threshold value. Hematology laboratory parameters assessed included hemoglobin (Hgb), platelet count, white blood cell count (WBC) and red blood cell (RBC) count. Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Threshold Hematology Value.
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Hgb, <0.75 X LLN, n=287, 29100
Platelet count, <0.75 X LLN, n=284, 28361
Platelet count, >1.50 X ULN, n=285, 28500
RBC, <0.50 X LLN, n=287, 29100
WBC, <0.50 X LLN, n=287, 29100
WBC, >3.00 X ULN, n=287, 29100
SecondaryNumber of Participants With Threshold Clinical Chemistry Value.

Clinical chemistry laboratory parameters assessed included albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatinine, glucose, potassium, sodium, total bilirubin, total protein and urea/blood urea nitrogen (BUN). Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Threshold Clinical Chemistry Value.
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
albumin, <0.90 X LLN, n=289, 29200
albumin, >1.20 X ULN, n=289, 29200
ALT, >3.00 X ULN, n=289, 29200
ALP, > 1.50 X ULN, n=289, 29200
AST, >3.00 X ULN, n=288, 29201
creatinine, <0.50 X LLN, n=289, 29200
creatinine, >3.00 X ULN, n=289, 29200
glucose, <0.70 X LLN, n=288, 29200
glucose, >1.75 X ULN, n=280, 2851313
potassium, <0.75 X LLN, n=288, 29200
potassium, >1.40 X ULN, n=288, 29200
sodium, <0.90 X LLN, n=289, 29200
sodium, >1.15 X ULN, n=289, 29200
total bilirubin, >2.50 X ULN, n=289, 29200
total protein, <0.80 X LLN, n=289, 29200
total protein, >1.15 X ULN, n=289, 29200
Urea/BUN, <0.50 X LLN, n=289, 29200
Urea/BUN, >2.00 X ULN, n=289, 29200
SecondaryNumber of Participants With Digital Rectal Examination (DRE)

DRE evaluation was carried out from normal/diffusely enlarged at Baseline to focal abnormalities at any time post-Baseline. DRE was assessed at screening visit, Month 6, 12, 18 , 24 and final assessment is the latest post-Baseline evaluation that was available. Here, participants with focal abnormalities are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
6, 12, 18 , 24 months and final assessment
Reported as:
Count of participants · Participants
Number of Participants With Digital Rectal Examination (DRE)
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, n=287, 285119
Month 12, n=279, 2721011
Month 18, n=267, 258612
Month 24, n=261, 2521013
Final Assessment, n=296, 2951015
SecondaryNumber of Participants With Clinically Significant Qualitative Breast Examination

Qualitative breast examination included palpable breast tissue and nipple tenderness. Here, participants with clinically significant abnormalities for palpable breast tissue and nipple tenderness are summarized. Qualitative breast examination was done at screening visit, Month 6, 12, 18 , 24 and final assessment (latest post-Baseline evaluation that was available). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
6, 12, 18 , 24 months and final assessment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Qualitative Breast Examination
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Palpable breast tissue, Month 6, n=289, 28400
Nipple tenderness,Month 6, n=289, 28400
Palpable breast tissue, Month 12, n=279, 27312
Nipple tenderness,Month 12, n=279, 27301
Palpable breast tissue, Month 18, n=267, 25810
Nipple tenderness,Month 18, n=267, 25800
Palpable breast tissue, Month 24, n=262, 25200
Nipple tenderness, Month 24, n=262, 25200
Palpable breast tissue,final assessment, n=296,29600
Nipple tenderness,final assessment, n=296, 29600
SecondaryNumber of Participants With Suicidal Ideation and Suicidal Behavior

Suicidality was assessed utilizing the Columbia Suicide Severity Rating Scale (C-SSRS). It included tabular summaries of suicidal ideation and suicidal behavior questions that were administered. Assessments were carried out at Screening, Month 6, Month 12, and Month 24 (or end of treatment) visits. C-SSRS included Question1-2 were for suicidal ideation Question 1: Passive: wish to be dead, Question 2: Active: Non-specific (no method, intent or plan). Questions 6-10 were for suicidal behavior, Question 6: Preparatory Acts or Behavior, Question 7: any aborted attempt, Question 8: Any interrupted attempts, Question 9: Any non-fatal actual suicide attempt, Question 10: Completed suicide. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
6, 12, 18 , 24 months and final assessment
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Suicidal Behavior
ParticipantsPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Month 6, Suicidal ideation, Q1, n=289, 28500
Month 6, Suicidal ideation, Q2, n=289, 28500
Month 6, Suicidal behavior, Q6, n=289, 28500
Month 6, Suicidal behavior, Q7, n=289, 28500
Month 6, Suicidal behavior, Q8, n=289, 28500
Month 6, Suicidal behavior, Q9, n=289, 28500
Month 6, Suicidal behavior, Q10, n=289, 28500
Month 12, Suicidal ideation, Q1, n=279, 27300
Month 12, Suicidal ideation, Q2, n=279, 27300
Month 12, Suicidal behavior, Q6, n=279, 27300
Month 12, Suicidal behavior, Q7, n=279, 27300
Month 12, Suicidal behavior, Q8, n=279, 27300
Month 12, Suicidal behavior, Q9, n=279, 27300
Month 12, Suicidal behavior, Q10, n=279, 27300
Month 24, Suicidal ideation, Q1, n=261, 25101
Month 24, Suicidal ideation, Q2, n=261, 25100
Month 12, Suicidal behavior, Q6, n=261, 25100
Month 12, Suicidal behavior, Q7, n=261, 25100
Month 12, Suicidal behavior, Q8, n=261, 25100
Month 12, Suicidal behavior, Q9, n=261, 25100
Month 12, Suicidal behavior, Q10, n=261, 25100
Final assessment, Suicidal ideation,Q1, n=288, 28501
Final assessment, Suicidal ideation,Q2, n=288, 28500
Final assessment, Suicidal behavior,Q6, n=288, 28500
Final assessment, Suicidal behavior,Q7, n=288, 28500
Final assessment, Suicidal behavior,Q8, n=288, 28500
Final assessment, Suicidal behavior,Q9, n=288, 28500
Final assessment, Suicidal behavior,Q10,n=288, 28500

Adverse events

Collected over Up to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Tam 0.2mg1/302 (0.3%)52/302 (17.2%)203/302 (67.2%)
Dut 0.5 mg + Tam 0.2 mg2/305 (0.7%)49/305 (16.1%)208/305 (68.2%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Large intestine polypGastrointestinal disorders7/3020/305
Inguinal herniaGastrointestinal disorders5/3022/305
Arteriosclerosis coronary arteryCardiac disorders2/3023/305
HaemorrhoidsGastrointestinal disorders2/3020/305
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3020/305
Cerebral infarctionNervous system disorders2/3020/305
BronchitisInfections and infestations2/3020/305
CataractEye disorders2/3020/305
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders2/3020/305
SyncopeNervous system disorders1/3022/305
Most frequent other events
Showing 10 of 468
Most frequent other events
EventPlacebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mg
Upper respiratory tract infectionInfections and infestations38/30224/305
NasopharyngitisInfections and infestations30/30237/305
DizzinessNervous system disorders16/30214/305
Back painMusculoskeletal and connective tissue disorders11/30214/305
Erectile dysfunctionReproductive system and breast disorders3/30214/305
ConstipationGastrointestinal disorders3/30213/305
BronchitisInfections and infestations11/3028/305
Gastrooesophageal reflux diseaseGastrointestinal disorders11/3027/305
ArthralgiaMusculoskeletal and connective tissue disorders11/3027/305
EczemaSkin and subcutaneous tissue disorders5/30211/305

Baseline characteristics

Intent-to-Treat Population, comprised of all randomized participants who received or did not receive study treatment

Age, Continuous
Age, Continuous(Years)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mgTotal
Mean66.2 ± 6.8566.8 ± 6.8266.5 ± 6.84
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mgTotal
Female000
Male302305607
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + Tam 0.2mgDut 0.5 mg + Tam 0.2 mgTotal
Asian - East Asian Heritage234236470
Asian - Japanese Heritage6867135
Asian - Southeast Asian Heritage022
08

Study locations

46 sites
  • GSK Investigational Site
    Xiame, Fujian, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510120, China
  • GSK Investigational Site
    Wuhan, Hubei 430030, China
  • GSK Investigational Site
    Suzhou, Jiangsu 215004, China
  • GSK Investigational Site
    Shenyang, Liaoning, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310003, China
  • GSK Investigational Site
    Beijing, 100020, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Beijing, 100730, China
  • GSK Investigational Site
    Chongqing, 400037, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200030, China
  • GSK Investigational Site
    Shanghai, 200032, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200433, China
  • GSK Investigational Site
    Fukuoka, 810-0001, Japan
  • GSK Investigational Site
    Fukuoka, 811-0120, Japan
  • GSK Investigational Site
    Hyogo, 651-1145, Japan
  • GSK Investigational Site
    Kanagawa, 226-0025, Japan
  • GSK Investigational Site
    Kanagawa, 252-0143, Japan
  • GSK Investigational Site
    Oita, 874-0937, Japan
  • GSK Investigational Site
    Osaka, 530-0013, Japan
  • GSK Investigational Site
    Saitama, 343-0845, Japan
  • GSK Investigational Site
    Tokyo, 150-0002, Japan
  • GSK Investigational Site
    Tokyo, 184-0005, Japan
  • GSK Investigational Site
    Yamanashi, 400-0124, Japan
  • GSK Investigational Site
    Busan, 614-735, Korea, Republic of
  • GSK Investigational Site
    Chonju, 561-712, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-712, Korea, Republic of
  • GSK Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • GSK Investigational Site
    Incheon, 405-760, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-720, Korea, Republic of
  • GSK Investigational Site
    Seoul, 136-705, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Seoul, 150-713, Korea, Republic of
  • GSK Investigational Site
    Seoul, 156-707, Korea, Republic of
  • GSK Investigational Site
    Chia-Yi, 613, Taiwan
  • GSK Investigational Site
    Hualien, 970, Taiwan
  • GSK Investigational Site
    Kaohsiung Hsien, 83301, Taiwan
  • GSK Investigational Site
    Kaohsiung, Taiwan
  • GSK Investigational Site
    New Taipei City, 23142, Taiwan
  • GSK Investigational Site
    Tainan, 704, Taiwan
  • GSK Investigational Site
    Tainan, 71004, Taiwan
  • GSK Investigational Site
    Tau-Yuan, 333, Taiwan
09

References and documents

Publications

  • Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, Brotherton B, Wilson T, Muganurmath C, McLaughlin M, Manyak M. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. Int J Urol. 2018 Nov;25(11):944-951. doi: 10.1111/iju.13785. Epub 2018 Sep 9. PubMed 30198102 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Mar 2017, 36 months.

Results were first posted in Apr 2019, 2 years 1 month after primary completion.

Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Feb 10, 2014
StartActual
Feb 10, 2014
Primary completionActual
Mar 3, 2017
CompletionActual
Mar 3, 2017
Results first posted
Apr 5, 2019
Last update
Apr 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02058368
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 10, 2014
Start date
Feb 10, 2014
Primary completion
Mar 3, 2017
Completion
Mar 3, 2017
Results posted
Apr 5, 2019
Last update
Apr 5, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion